Latest Conference Articles

Targeted Therapies, Immunotherapies Slated to Propel T-cell ALL Treatment Paradigm Forward

The cure rate for patients with T-cell acute lymphoblastic leukemia has improved dramatically over the past few decades, with outcomes becoming comparable to what is observed in those with B-cell acute lymphoblastic leukemia.

TDM-1/Osimertinib Combo Has Limited Efficacy for Resistant EGFR+ NSCLC

The combination of ado-trastuzumab emtansine and osimertinib demonstrated minimal antitumor effects on patients with EGFR-mutated non–small cell lung cancer, according to interim data of the phase 2 TRAEMOS trial.

Dr. Cortes on Emerging Therapies in CML

Jorge E. Cortes, MD, discusses emerging therapies in chronic myeloid leukemia.

Selpercatinib Elicits Durable Antitumor Activity in Advanced RET Fusion+ NSCLC

Selpercatinib demonstrated robust and durable efficacy with a favorable safety profile in Chinese patients with advanced, RET fusion–positive non–small cell lung cancer.

Sotorasib Induces Intracranial Activity in KRAS G12C–Mutated NSCLC Brain Metastases

Sotorasib elicited systemic durable anticancer activity with intracranial complete responses and continued intracranial stabilization in patients with KRAS G12C–mutated non–small cell lung cancer and stable brain metastases previously treated with radiation or surgery.

COVID-19 Leads to High Hospitalization and Mortality in Malignant Pleural Mesothelioma

Approximately 20% of patients with malignant pleural mesothelioma were diagnosed with COVID-19 during the first year of the pandemic at the Vall d’Hebron University Hospital, leading to a high hospitalization and mortality rate.

Tislelizumab Plus Chemotherapy Elicits PFS Benefit in Advanced Squamous NSCLC

Tislelizumab plus chemotherapy demonstrated clinically meaningful improvements in progression-free survival vs standard of care chemotherapy as a first-line treatment for patients with stage IIIB and those with stage IV advanced squamous non–small cell lung cancer.

Pelcitoclax/Osimertinib Combo Shows Preliminary Effiacy in EGFR+ NSCLC

The combination of osimertinib plus pelcitoclax demonstrated an acceptable safety profile and preliminary efficacy at the recommended phase 2 dose in patients with EGFR-positive non–small cell lung cancer that is resistant to third-generation EGFR inhibitors or treatment naïve.

Novel, Emerging Approaches Set the Stage for Advancement in cGVHD

In recent years, significant advances have been made regarding the treatment of patients with chronic graft-vs-host disease, with investigators developing an understanding of the pathophysiology of the disease, as well as how to integrate novel treatment modalities.

Pralsetinib Elicits Promising Activity in Advanced RET Fusion+ NSCLC

In patients with advanced RET fusion–positive non-small cell lung cancer, pralsetinib demonstrated promising results regardless of previous therapies.

Mobocertinib Shows Superior PROs in Previously Treated EGFR Exon 20+ Metastatic NSCLC

Mobocertinib improved patient-reported outcomes in those with previously treated non–small cell lung cancer whose tumors harbored EGFR exon 20 insertion mutations.

ADP-A2AFP SPEAR T Cells Demonstrate Efficacy, Tolerability in Advanced HCC

ADP-A2AFPspecific peptide enhanced affinity receptor T cells were associated with an acceptable safety profile and elicited antitumor activity in patients with advanced hepatocellular carcinoma.

Nivolumab Continues to Elicit Durable Responses in Advanced Hepatocellular Carcinoma

Nivolumab elicited a prolonged clinical benefit in patients with advanced hepatocellular carcinoma regardless of prior sorafenib.

Investigators Look to Overcome Resistance in Advanced HCC With Triplet Combinations

Triplet regimens leveraging novel agents targeted at overcoming mechanisms of resistance in combination with immune checkpoint inhibitors and anti-angiogenic therapies represent the next frontier in hepatocellular carcinoma.

Dr. Pinato on Guidelines for Toxicity Management in HCC

David J. Pinato, MD, discusses guidelines for toxicity management in hepatocellular carcinoma (HCC).

Atezolizumab/Bevacizumab Improves OS in Albumin-Bilirubin Grade 1 HCC

The combination of atezolizumab and bevacizumab elicited an improved overall survival benefit compared with sorafenib in patients with albumin-bilirubin grade 1 hepatocellular carcinoma, according to findings from an exploratory subgroup analysis of the phase 3 IMbrave150 trial.

High Interferon Signaling and Antigen Presentation Predicts for Response Only in Frontline Advanced HCC

Biomarkers of response to immunotherapy, characterized by high interferon signaling and expression of MHC-II related genes, predicted for improved survival in patients with advanced hepatocellular carcinoma following immediate treatment with a PD-1 inhibitor but not in those who had first received treatment with a TKI.

Dr. Vogel on the Utility of Frontline Lenvatinib or Sorafenib in HCC

Arndt Vogel, MD, discusses the utility of frontline lenvatinib or sorafenib in hepatocellular carcinoma.

Dr. Singal on the Results of a Mailed Outreach Strategy for Surveillance Utilization in HCC

Amit Singal, MD, discusses the results of a study evaluating the utilization of a mailed surveillance outreach program in hepatocellular carcinoma.

Dr. Rich on the Prevalence of Cachexia in HCC

Nicole Rich, MD, discusses the prevalence of cachexia in hepatocellular carcinoma.

SIRT With Y90 Plus Chemotherapy Extends Survival for Intrahepatic Cholangiocarcinoma

Dual Checkpoint Blockade/Ablation Regimens Show Intriguing Activity in Advanced HCC

Combining durvalumab and tremelimumab plus transcatheter arterial chemoembolization or radiofrequency ablation was found to be both efficacious and safe as a treatment for patients with advanced hepatocellular carcinoma, according to results of a pilot study.

Predictive Biomarkers for Checkpoint Inhibition Remain Unmet Need in HCC

Josep M. Llovet, MD, discusses the importance of identifying biomarkers of response to checkpoint inhibitors for patients with hepatocellular carcinoma, as well as future research directions.

New and Updated Findings Showcase a Shift With Immunotherapy Across Melanoma

Data that emerged from the 2021 ASCO Annual Meeting represent potential paradigm shifts for patients with advanced melanoma.

Non–CAR T-Based Strategies Shake Up the Management of Non-Hodgkin Lymphoma

Stephen M. Ansell, MD, PhD, discusses recent progress made with non–CAR T-based approaches in the non-Hodgkin lymphoma treatment paradigm, opportunities for sequencing available options, and ongoing efforts that are picking up momentum.

BTK Inhibitors Represent the Preferred Frontline Regimen in CLL

The majority of patients with newly diagnosed chronic lymphocytic leukemia have better outcomes with BTK inhibitors compared with standard chemoimmunotherapy, making them the logical choice for frontline therapy.

Zanubrutinib Shows Encouraging Tolerability, Activity in BTK Inhibitor–Intolerant B-Cell Malignancies

Zanubrutinib demonstrated clinical activity and tolerability in previously treated patients with B-cell malignancies who were intolerant to therapy with ibrutinib and/or acalabrutinib, according to results of the phase 2 BGB-3111-215 trial.

Standardized Guidelines Support Management Strategies of CAR T-Cell Therapy–Related Toxicities

As more CAR T-cell therapies are approved for the treatment of patients with hematologic malignancies, adopting management strategies for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome using newly standardized grading criteria is an important component of utilizing these products in practice.

Acalabrutinib Induces Durable Disease Control in Frontline CLL at 4 Years

Acalabrutinib, alone or in combination with obinutuzumab, demonstrated superior efficacy and an acceptable safety profile in patients with treatment-naïve chronic lymphocytic leukemia.

Loncastuximab Tesirine and Ibrutinib Combination Shows Promise in R/R DLBCL and MCL

The combination of loncastuximab tesirine-lpyl and ibrutinib displayed encouraging antitumor activity with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma and mantle cell lymphoma.